Changes coming in 2010 for first-line treatment of multiple myeloma

Submitted by Ross Bonander Sun 01/17/2010

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

According to a study published by Majestic Research's Market Research Group, data presented at the 2009 American Society of Hematology (ASH) 2009 Annual Meeting in December has had a profound effect on the way many hematologists and oncologists intend to treat multiple myeloma, a cancer of the plasma cells.

Specifically, almost half of those specialists polled say they expect to start using the thalidomide analog Revlimid (lenalidomide), the antineoplastic agent Velcade (bortezomib), or both in combination.

In this context, the most recalled study from ASH was MM-015, a Phase III study that looked at the continuous use of Revlimid with Melphalan and Prednisone. Research shows that many experts believed that the results of MM-015 were significant enough to encourage using Revlimid in treating multiple myeloma.

In short, this year we should expect a substantial change to the first-line treatment of this difficult-to-treat cancer.

By Ross Bonander

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.